Navigation Links
Nile Therapeutics, Inc. To Raise $3.4 Million in Private Placement
Date:7/8/2009

SAN FRANCISCO, July 8 /PRNewswire-FirstCall/ -- Nile Therapeutics, Inc. (Nasdaq: NLTX), a company focused on the development of novel therapeutics for heart failure patients, today announced that it has received commitments from investors to purchase in a private placement securities of the Company for aggregate gross proceeds of approximately $3.4 million. Riverbank Capital Inc., a FINRA member broker dealer, acted as the exclusive placement agent for the transaction.

The net proceeds of the financing will be used to support the advancement of Nile's lead compound, CD-NP, through its 30-patient single-blind, placebo-controlled Phase 2 study, which is currently open to enrollment. This Phase 2 study is designed to provide additional information on the safety and tolerability of CD-NP when infused for up to 72 hours in patients with acute heart failure and mild to moderate renal insufficiency. Additional exploratory endpoints will include assessments of CD-NP's ability to relieve symptoms of acute heart failure and its effects on biomarkers of heart failure and renal function.

"We are pleased to have the continued support of the investment community to ensure the advancement of our promising technology in the effort to develop a novel treatment for heart failure patients," said Joshua Kazam, Chief Executive Officer. "We believe these funds will provide us with sufficient capital to complete our impending Phase 2 clinical study of CD-NP and we look forward to generating meaningful clinical data."

Under the terms of a Securities Purchase Agreement, Nile will sell an aggregate of approximately 2.7 million shares of its common stock and warrants to purchase up approximately 2.7 million additional shares of its common stock. Each unit, consisting of one share of common stock and a warrant to purchase one share of comm
'/>"/>

SOURCE Nile Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Intarcia Therapeutics, Inc. Presents ITCA 650 Phase 1b Study Results as a Late-Breaker at the American Diabetes Association 69th Scientific Sessions
2. Intarcia Therapeutics, Inc. Announces Acceptance of ITCA 650 Phase 1b Study for Late-Breaker Presentation at the American Diabetes Association 69th Scientific Sessions
3. Prospect Therapeutics, Inc.s GCS-100 Inhibited Blood Vessel Formation in a Variety of Cancer Models
4. Cell Therapeutics, Inc. (CTI) to Present at 2009 BIO International Convention
5. Prospect Therapeutics, Inc. Assigns All Its Assets to Joseph F. Finn, Jr., C.P.A. for the Benefit of Its Creditors
6. Cell Therapeutics, Inc. (CTI) to Report 2009 First Quarter Financial Results on May 7
7. Oxygen Biotherapeutics, Inc. Signs Supply Agreement for Clinical-Grade Oxycyte for Clinical Trials and Future Needs
8. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $15 Million of Preferred Stock
9. Oxygen Biotherapeutics, Inc. CEO Posts New Blog Entry
10. Stockholder Suits Related to TorreyPines Therapeutics, Inc. Dismissed
11. Webcast Alert: Oxygen Biotherapeutics, Inc. Investor Meeting in Zurich, Switzerland
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... MD (PRWEB) August 21, 2014 DNA ... making progress in its development of JRC-LAMP-vax, an innovative ... cedar pollen. Phase IC studies began this month in ... to hay fever. , The Japanese red cedar releases ... people in Japan. Mountain Cedar pollen wreaks similar havoc ...
(Date:8/21/2014)... (PRWEB) August 21, 2014 His Majesty ... Opening , The Court of His Majesty Willem-Alexander, King ... attend the Grand Opening of POET-DSM Advanced Biofuels’ Project ... Sept. 3. , The King will take part in ... activity, scheduled for 11 a.m.-12:20 p.m. and tour the ...
(Date:8/21/2014)... OTC Markets Group Inc. ... company, on its approval to list on The ... the best marketplace for established U.S. and global ... Logo - http://photos.prnewswire.com/prnh/20110118/MM31963LOGO "We ... its growth strategy and achievement of this important ...
(Date:8/21/2014)... 21, 2014 Gallus BioPharmaceuticals ... development and manufacturing organization (CMO) announced today that ... an oncology company focused on the development of ... manufacture the anti-prostate specific membrane antigen (PSMA) monoclonal ... Under the agreement the antibody will be ...
Breaking Biology Technology:Relief for Allergy Sufferers Finally in Sight: Immunomic Therapeutics Closes in on Treatment for Hay Fever in Japan, U.S. 2Relief for Allergy Sufferers Finally in Sight: Immunomic Therapeutics Closes in on Treatment for Hay Fever in Japan, U.S. 3Relief for Allergy Sufferers Finally in Sight: Immunomic Therapeutics Closes in on Treatment for Hay Fever in Japan, U.S. 4His Majesty Willem-Alexander, King of the Netherlands, to Attend Project LIBERTY opening 2His Majesty Willem-Alexander, King of the Netherlands, to Attend Project LIBERTY opening 3OTC Markets Group Congratulates Immune Pharmaceuticals on NASDAQ Listing 2Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 2Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 3
... there was a monopoly phone service prior to the 1984 ... exclusivity in the territory and we will provide universal service ... a geographic subscriber base, the traditional phone companies ensured that ... fair price. There was one price across the board. That ...
... - Does the Wisconsin Alumni Research Foundation's ... for approval? , ,The foundation's stem cell patent is ... it is overly broad and is suppressing scientific research. ... the more than 300 academic licenses it has issued ...
... to clarify the definition of records for the treatment ... incorporate them into Electronic Health Records, has been signed ... 650 creates an exception to current law pertaining to ... to mental health records when they are treating patients ...
Cached Biology Technology:Does redefining universal service help bridge the digital divide? 2Does redefining universal service help bridge the digital divide? 3Does redefining universal service help bridge the digital divide? 4Does redefining universal service help bridge the digital divide? 5WARF stem cell patent faces long and winding road 2WARF stem cell patent faces long and winding road 3WARF stem cell patent faces long and winding road 4WARF stem cell patent faces long and winding road 5
(Date:8/22/2014)... a leading source of information for businesses and professionals, ... Riverside in its 2014 list of "some of the ... generate the list, the company analyzed citation data over ... has had enormous impact. , The following UC Riverside ... the greatest number of highly cited papers in one ...
(Date:8/22/2014)... NAIROBI (22 August 2014)With ... as a major threat to food security across the continent, ... five years, 1.7 million African farmers in 13 countries have ... helped them double or even triple crop yields. , The ... (AGRA) focuses on intensive efforts initiated five years ago to ...
(Date:8/22/2014)... FASEB MARC (Maximizing Access to Research Careers) Program ... Grant Writing Seminar & Practical Exercises Workshop which will ... Maryland from August 25-26, 2014. These awards are ... research scientists from underrepresented groups in the the FASEB ... year MARC conferred 11 awards totaling $20,350. , The ...
Breaking Biology News(10 mins):5 UC Riverside scientists among world's most influential scientific minds 2Effort to confront Africa's soil health crisis helps millions of farmers triple yields 2Effort to confront Africa's soil health crisis helps millions of farmers triple yields 3Effort to confront Africa's soil health crisis helps millions of farmers triple yields 4
... next generation sequencing (NGS) and Certified Service Provider for ... a leading company in complex analysis and interpretation of ... complete human exome array, based on Roche NimbleGen sequence ... comprehensive service for human exome capture, targeted re-sequencing and ...
... be used to "see" something as small as an ... has once again overturned conventional wisdom. Secretary of Energy, ... National Laboratory (Berkeley Lab) Steven Chu led the development ... microscopy to ,image objects or the distance between them ...
... of all acute leukemias represents a small population of ... standard treatments available today. Though current chemotherapy can produce ... of experiencing a recurrence and dying from the disease. ... rare form of leukemia called acute promyelocytic leukemia (APL), ...
Cached Biology News:Eurofins MWG Operon and Genomatix developed most complete human exome array 2Correcting a trick of the light brings molecules into view 2Correcting a trick of the light brings molecules into view 3Correcting a trick of the light brings molecules into view 4Grant to fund research into eradicating the leukemia stem cell 2
Request Info...
Request Info...
Human acetylcholine receptor (AChR)-alpha. Exhibits homogenous, high affinity,binding to the receptor. Binds weakly to a64-78. Inhibits binding of many,myasthenia gravis sera to human AChR....
...
Biology Products: